Drug reference

Levodopa, Carbidopa, and Entacapone

Dopamine Agonist · Anti-Parkinsonian Agent

Also known as Stalevo

Dopamine AgonistAnti-Parkinsonian Agent

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

Levodopa, a precursor to dopamine, crosses the blood-brain barrier and is converted to dopamine in the brain to replenish deficient levels in Parkinson's disease. Carbidopa inhibits peripheral DOPA decarboxylase, preventing levodopa's conversion to dopamine outside the brain, thus increasing its availability for cerebral action and reducing peripheral side effects. Entacapone, a COMT inhibitor, prevents the breakdown of levodopa by catechol-O-methyltransferase, thereby extending levodopa's half-life and duration of action.

Indications

Parkinson’s disease and end-of-dose motor fluctuations not adequately controlled with levodopa and dopa-decarboxylase inhibitor treatment

Dosing

Adult: Oral: 1 tablet for each dose. Specific maximum daily doses vary by strength: for STALEVO® 100/25/200, 125/31.25/200, 150/37.5/200, 50/12.5/200, 75/18.75/200, maximum 10 tablets per day. For STALEVO® 175/43.75/200, maximum 8 tablets per day. For STALEVO® 200/50/200, maximum 7 tablets per day.…
Max dose: Maximum 10 tablets per day for STALEVO® 100/25/200, 125/31.25/200, 150/37.5/200, 50/12.5/200, 75/18.75/200. Maximum 8 tablets per day for STALEVO® 175/43.75/200. Maximum 7 tablets per day for STALEVO® 200/50/200.